ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval

Stock News

2025/08/20

ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.

In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is "An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations."

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1128157469"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128157469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128157469?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128157469","market":"nz","top_or_hot":-1,"title":"ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval","media":"Stock News","content":"<p>ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.</p>\n<p>In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nABBISKO-B (02256): IND Application for Combination Therapy of Oral PD-L1 Inhibitor ABSK043 and Shanghai Allist's KRAS G12C Inhibitor for NSCLC Treatment Receives CDE Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-20 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.</p>\n<p>In March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1128157469","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128157469","pubTimestamp":1755689504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688578":"艾力斯","BK1515":"抗疫概念","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","CDE":"科尔黛伦矿业","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK1161":"生物科技","BK4023":"应用软件","LU1223082196.USD":"施罗德环球黄金A Acc","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","PD":"PagerDuty, Inc.","BK4017":"黄金","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","09939":"开拓药业-B","02256":"和誉-B","BK0239":"医药制造"},"translate_title":"和必施-B（02256）：口服PD-L1抑制剂ABSK043与上海艾利斯特KRAS G12C抑制剂联合疗法治疗非小细胞肺癌IND申请获CDE批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688578":1,"09939":1,"CDE":1,"PD":1,"02256":1},"content_text":"ABBISKO-B (02256) announced that the IND application for combination therapy using its subsidiary's investigational oral PD-L1 inhibitor ABSK043 and Shanghai Allist Pharmaceuticals Co.,Ltd.'s KRAS G12C inhibitor citrate golaresetib tablets for treating non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations has been approved by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration.\nIn March 2025, the company's subsidiary reached a collaboration agreement with Shanghai Allist Pharmaceuticals regarding the combination use of ABSK043 and citrate golaresetib tablets. The approved study is \"An open-label Phase II clinical trial evaluating the safety, tolerability, and efficacy of ABSK043 combined with citrate golaresetib tablets in patients with locally advanced or metastatic NSCLC harboring KRAS G12C mutations.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}